Is It Time to Invest in Pharmaceutical Stocks After Their Best Week in 20 Years?

by

Well, well, well. Pharmaceutical stocks, those rather staid and sober members of the stock market, have decided to throw a little party. The S&P 500 Pharmaceuticals Index just experienced its best week in over two decades, leaping 11% over five trading days. It’s like they finally caught up with the tech stocks in terms of excitement. But here’s the thing-do we really believe this new-found joy is sustainable? Or are we just getting swept up in the hype, like the time we all thought *The Great Gatsby* was about endless summer parties and not existential loneliness?

Now, enter the VanEck Pharmaceutical ETF (PPH), which has seen a tidy 9% increase over the past two weeks-before, of course, the market’s usual plunge on Oct. 10. This fund tracks the MVIS US Listed Pharmaceutical 25 Index, which, while not the snazziest name in the market, measures the performance of the top 25 U.S.-listed pharmaceutical companies. If you’re wondering whether it’s diversified, let’s just say it’s about as diversified as a well-stocked wine cellar. And that’s a good thing, right?

Loading widget...

Here’s what’s got the market all aflutter: it’s the hope, dare I say the *expectation*, that the Trump administration’s tariff threat on drug imports has been, well, defused for the time being. Trump’s big, bold, 100% tariff talk on branded and patented drugs-remember that dramatic September build-up?-has been dialed back. It seems that his Oct. 1 deadline has come and gone without the promised fireworks. Instead, the White House has decided to “let negotiations play out,” which, for anyone who’s watched Washington in action, likely means we’re in for a few more weeks of “Are we doing this or not?” drama.

100% Tariffs: A Rhetorical Gambit

It all started with that September bombshell: a potential 100% tariff on drugs. And then, lo and behold, Pfizer swooped in like a corporate knight in shining armor, striking a deal to offer lower prices in exchange for a three-year tariff holiday. Can you believe it? A *three-year* break from tariffs. All they had to do was pledge a $70 billion investment to boost U.S. manufacturing. Other pharmaceutical giants quickly followed suit-Johnson & Johnson, Merck, Eli Lilly-each promising billions of dollars in investment. Together, they’ve committed to $350 billion in U.S. manufacturing. All of this, mind you, to avoid being crushed under a giant tariff heel. So, the tariffs that were supposed to be the great threat to the industry… evaporated. Almost as if they were never really meant to happen in the first place. Quite the plot twist, really.

New Investments: The Calm After the Storm

It seems that the drug industry, so accustomed to being *the adult in the room* (with all the joy that brings), might just get a break. In fact, if you’re of the mind that this situation is only going to improve, investing in pharmaceutical stocks may be an idea that doesn’t keep you up at night. The VanEck Pharmaceutical ETF, a fund boasting $545 million in assets, could be your entry point. After all, it’s diversified, both in terms of stocks (26 in total) and geography (U.S., U.K., Switzerland, Denmark… you name it).

The fund’s top holdings include:

  • Eli Lilly, a whopping 19.6%
  • Novartis (NVS), 9.7%
  • Novo Nordisk (NVO), 8%
  • Merck, 7.2%
  • McKesson and Pfizer, both at 4.9%

And here’s a little gem: the fund’s management fee is a mere 0.36%. Not bad, considering the average ETF is often swimming in higher fees. In fact, this puts the fund in the lowest quintile among its peers, according to Morningstar. All in all, it’s a solid bet for someone who’s looking to dip a toe into the pharmaceutical waters without getting too carried away.

So, what does this all mean for you, dear investor? Well, it could mean you’re looking at an opportunity to invest in a sector that’s been given a new lease on life-at least for now. But before you run off to fill your portfolio with pharma stocks, remember that the future of Trump’s policies is about as predictable as British weather. And while cheaper drugs and more U.S. manufacturing sound promising, the world of politics is never as straightforward as it seems. But hey, *if* things pan out, it could be a win-win for everyone: lower drug prices, more U.S. jobs, and-fingers crossed-some healthy returns for investors. Let’s keep an eye on it, shall we?

Units of optimism gained: 17. Stock charts reviewed: 56. Hours spent re-evaluating investment strategy: 4. Days until the next market rollercoaster: Who knows? 🤔

Read More

2025-10-13 13:34